Has Jerrie Morales, APRN received payments from drug or device companies?

Yes. Drug and device makers reported $14,700 in general payments to Jerrie Morales, APRN across 644 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jerrie Morales, APRN did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jerrie Morales, APRN come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jerrie Morales, APRN

Acute Care · Tulsa, OKNPI 1962975458

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 644 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 24.4% of the total. Among acute care clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,700in general payments, 2019–2025

Across 644 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$4K
Amgen$3K
AstraZeneca$1K
UCB, Inc.$987
Johnson & Johnson$922
Novartis$732
plus $4K from 15 others

What the payments were for

Food & beverage$14,628100%
Education$720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	190	$3,588
Amgen(2 entities)	142	$3,134
AstraZeneca	47	$1,460
UCB, Inc.	44	$987
Johnson & Johnson	30	$922
Novartis	38	$732
Pfizer	34	$702
GSK	22	$484
Mallinckrodt Hospital Products Inc.	14	$461
Boehringer Ingelheim	17	$433
Lilly USA, LLC	16	$426
Sanofi	5	$277
Aurinia Pharma U.S., Inc.	15	$262
Janssen Scientific Affairs, LLC	2	$250
ANI Pharmaceuticals, Inc.	9	$206
E.r. Squibb & Sons, L.L.C.	7	$172
Fresenius Kabi USA, LLC	4	$66
Sandoz	2	$47
Azurity Pharmaceuticals, Inc.	2	$32
Tersera Therapeutics LLC	2	$31
Genentech USA, Inc.	2	$27

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,700 in reported general payments places this provider in the 95th percentile of 266 acute care providers in Oklahoma.

See all acute care providers in Oklahoma →

Medicare billing

Part B allowed, 2024

$58,684

Medicare patients

403

Services billed

2,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RinvoqUpadacitinib	23	$153,670
Humira(Cf) PenAdalimumab	14	$92,997
Enbrel MiniEtanercept	11	$76,552
Orencia ClickjectAbatacept	11	$72,894
Xeljanz XrTofacitinib Citrate	12	$71,601
ActemraTocilizumab	12	$54,920
Hydroxychloroquine Sulfate	338	$18,890
EliquisApixaban	12	$11,184
MethotrexateMethotrexate Sodium	195	$5,927
Leflunomide	73	$4,781
Sulfasalazine DrSulfasalazine	85	$3,787
Gabapentin	104	$3,548
Celecoxib	48	$2,057
Azathioprine	32	$1,705
Diclofenac Sodium	45	$1,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieRinvoq	$3,588	$153,67023 claims
PfizerEliquis	$702	$11,18412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 266 acute care providers in Oklahoma.

Other acute care in Tulsa

See the full list for Oklahoma →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →